Foresite Capital Fund IV, L.P. 13D and 13G filings for Lyell Immunopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 4:04 pm Purchase | 2025-03-31 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 1,358,095 9.200% | 384,150 (+39.44%) | Filing |
| 2025-02-14 2:20 pm Purchase | 2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 973,945 6.700% | 289,752 (+42.35%) | Filing |
| 2024-10-31 6:00 pm Purchase | 2024-10-25 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 684,193 5.300% | 184,193 (+36.84%) | Filing |
| 2023-02-13 5:02 pm Sale | 2022-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 500,000 4.000% | -164,109 (-24.71%) | Filing |
| 2022-02-11 3:10 pm Purchase | 2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL | Foresite Capital Fund IV, L.P. | 664,109 5.500% | 664,109 (New Position) | Filing |